PTPaulina Tegethoff

Paulina Tegethoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Paulina Tegethoff has a total of 166 co-authors. Here are the top co-authors by number of shared publications:

  • Carolin Kurz

    Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

    5 shared publications
  • Robert Perneczky

    Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany

    4 shared publications
  • Marleen Taute

    Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

    3 shared publications
  • Robert Perneczky

    Department of Psychiatry and Psychotherapy, LMU Hospital, LMU Munich, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK; Division of Neuroscience, University of Sheffield, Sheffield, UK

    3 shared publications
  • Anna Hufnagel

    LMU Hospital, LMU Munich

    2 shared publications
  • Anna Hufnagel

    Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany

    2 shared publications

Latest Publications

  • Open Access

    Diagnostic accuracy of a self-administered digital cognitive test battery for differentiating early Alzheimer’s disease from controls

    by Sophia Rutt, Paulina Tegethoff, Marleen Taute, Fortese Neziraj, Anna Hufnagel, Robert Perneczky, Carolin Kurz, Boris-Stephan Rauchmann

    Background: Paper-pencil assessments face limitations in accessibility, lengthy administration, and interrater reliability. Digital tools may overcome these by offering user-friendly, non-verbal, and scalable assessments. This study investigated the diagnostic accuracy of BraincheX, a novel digital test battery focused on accessibility and usability, by comparing its subtest performance to CERAD-Plus equivalents. Methods: Fifty-six participants with early AD and amyloid negative cognitively healthy controls were recruited from the LMU hospital memory clinic. Diagnostic groups were defined by amyloid positivity and clinical expert consensus according to the IWG-2 criteria. Participants completed the BraincheX digital battery and CERAD-Plus. BraincheX total score was calculated by summing standardized subtest scores. Data were analyzed using ROC analysis and the Youden Index. Correlations between subtests were examined, and group differences analyzed via ANOVA. Results: ROC analysis revealed strong diagnostic accuracy for the BraincheX total score in differentiating between early AD and controls (AUC = 0.86; optimal cut-off = − 1.51), with high sensitivity of 89.7% and moderate specificity of 68.0%. BraincheX total scores correlated with CERAD total scores ( r = .73, p < .001). BraincheX demonstrated good internal consistency (Cronbach’s α = 0.84). ANOVA confirmed significant group differences across all BraincheX subtests ( p < .01). Individual subtests showed strong correlations with CERAD-Plus equivalents. Conclusions: Findings suggest BraincheX as a promising, accessible digital screening tool for cognitive decline, offering automated scoring, immediate feedback, and reduced examiner bias. Future research is required to validate BraincheX in larger and more diverse populations and to establish BraincheX’s clinical applicability. Trial Registry: This analysis was conducted within the framework of the prospectively registered German SCD-Q validation study (NCT06711952). The registered study protocol included digital cognitive testing as part of the assessment protocol. The present manuscript reports a secondary analysis focusing on the diagnostic performance of BraincheX.


  • Open Access

    A multimodal framework for the assessment of decision-making capacity in neurocognitive disorders

    by Carolin Isabella Dr. Kurz, Paulina Tegethoff, Johanna Gelz, Iliana Gkempelsi, Anna Hufnagel, Fortese Neziraj, Pia Schuhbauer, Hannah Rahn, Myriam Boeck, Leonie Keidel, et al.

    BackgroundDecision-making capacity (DMC) is a prerequisite for valid informed consent, as well as being a key methodological requirement in clinical and epidemiological research. For individuals with neurocognitive disorders, DMC assessment is frequently based on subjective clinical judgement, with limited standardization and significant variability across settings. Current instruments are resource-intensive and not sufficiently adapted for stage-specific or real-world applications.ObjectiveTo develop a standardized, multimodal framework for assessing decision-making capacity, integrating neuropsychological, biological and contextual dimensions, and to define a validation strategy.MethodsWe propose a modular assessment framework that operationalizes the core domains of decision-making capacity: understanding, appreciation, reasoning and expression of choice. This is complemented by neuropsychological profiling, informant-based measures and structured decision scenarios. The framework is embedded in a prospective, multimodal cohort design spanning the neurocognitive disease spectrum. Validation is based on criterion-reference standards (MacCAT-T, CDR), psychometric analyses (factor analysis, reliability, ROC) and the integration of biological markers of neurodegeneration and disease stage. The co-design approach thus integrates both patient and caregiver perspectives as well as clinician and expert input, with focus group interviews providing a complementary, structured format to capture interdisciplinary professional perspectives.ResultsThe framework enables the structured, domain-specific and scalable assessment of decision-making capacity. It provides standardized scoring and quantifiable outputs, as well as a basis for stage-sensitive interpretation. It also allows the integration of biological context and real-world decision scenarios, thus facilitating both clinical applicability and research implementation.ConclusionsThis methodological framework provides a standardized, reproducible approach to assessing decision-making capacity in cognitively vulnerable populations. By integrating cognitive, biological and contextual dimensions, it enables more transparent, quantifiable and generalizable capacity assessment, with potential applications in clinical trials, observational studies and the design of ethically and legally compliant research.

  • Open Access

    Screening for Alzheimer’s disease in the community using an AI-driven screening platform: design of the PREDICTOM study

    by Anna-Katharine Brem, Zunera Khan, Jonas Radermacher, Kostas Georgiadis, Ioulietta Lazarou, Margarita Grammatikopoulou, Ellie Pickering, Johanna Mitterreiter, Jon Arild Aakre, Nicholas J. Ashton, et al.


  • Open Access

    Motivation, Worries and Digital Affinity in Cognitive Screening - Qualitative Findings From the CogScreen Study

    by Paulina Tegethoff, Robert Perneczky, Marleen Taute, Amy Deckert, Michael Hornbecker, Sophia Rutt, Anna Hufnagel, Soeren Mattke, Carolin Kurz

    Background: Subjective cognitive decline is considered one of the earliest signs of Alzheimer’s disease (AD), making early detection crucial for disease-modifying treatments to have the greatest impact. The CogScreen study, supported by the Davos Alzheimer’s Collaborative Healthcare System Preparedness Program, evaluates tools for community-based screening of AD in its early stages. This study investigates subjective experiences, focusing on motivations, concerns, and potential improvements regarding digital tools used in cognitive assessments. Methods: Semi-structured qualitative interviews were conducted with a random selection of 28 participants with subjective cognitive decline or healthy controls. Interviews were transcribed and analyzed using conventional content analysis (MAXQDA, VERBI Software, 2024). Results: Analysis identified emergent themes related to the usability of digital tools, the importance of clear communication, and the desire for a more personalized research experience. Participants highlighted motivations and concerns regarding the implementation of digital assessments. Discussion: Findings support the feasibility of integrating digital assessments in aging populations and underscore the importance of addressing participants’ motivations, concerns, and digital affinity when introducing innovative tools into clinical practice. Conclusion: Insights from this study contribute to future participant engagement strategies and the development of early detection methods for cognitive impairment. Trial Registration: CogScreen is registered at ClinicalTrials.gov (NCT06191952).


  • Open Access

    Motivation, Worries and Digital Affinity in Alzheimer's Disease Research ‐ Qualitative Findings from Davos Alzheimer's Collaborative

    by Paulina Tegethoff, Carolin Isabella Kurz, Anna Hufnagel, Sophia Rutt, Robert Perneczky

    Background: Subjective cognitive deficits are the earliest clinical sign of Alzheimer's disease (AD), raising interest in early detection when disease‐modifying drugs promise the greatest benefit. The CogScreen 1 and 2 studies, part of the Davos Alzheimer's Collaborative's Healthcare Systems Preparedness program, evaluate tools for community‐based screening for AD in the earliest clinical stages. During the studies, a systematic investigation of participant motivations, concerns, and suggestions for trial improvement emerged as essential. Methods: A qualitative interview guide was developed and applied in 30 telephone interviews with randomly assigned former participants. Recorded and transcribed data were analyzed using the MAXQDA software (VERBI Software), employing an inductive‐deductive coding guide. Thematic content analysis identified key patterns and insights into the motivation, concerns and digital affinity of participants in an AD research study. Results: The study uncovered valuable perspective on Alzheimer´s research. Participants revealed diverse motivations for involvement, ranging from personal connections to dementia to aspirations for early diagnosis and treatment. Reactions to potential diagnoses ranged from shock and grief to proactive care strategies. Digital affinity varied but showed encouraging levels of familiarity with technology among older adults. Participants raised concerns about the study design, including item clarity and response scales, as well as suggestions for improving digital and traditional tools. Conclusion: By systematically capturing participant feedback, the CogScreen study provides critical insights for improving AD research methodologies, particularly in relation to the participatory nature of research. These findings underline the importance of addressing participants' motivations and fears while integrating innovative tools. The results also highlight the feasibility of digital interventions in ageing populations and emphasize trust in public institutions. Future studies should use these findings to refine early detection approaches and encourage greater participant engagement.

  • Open Access

    A Self-Administered Digital Test Battery for Early Detection of Cognitive Impairment in Alzheimer’s Disease

    by Sophia Rutt, Marleen Taute, Paulina Tegethoff, Robert Perneczky, Carolin Kurz, Boris-Stephan Rauchmann

    Introduction Early detection of cognitive decline is crucial for timely intervention in Alzheimer’s disease (AD). Traditional paper-pencil assessments often face limitations in accessibility, lengthy administration, and interrater reliability, restricting their broader application across diverse populations. Digital tools may overcome these restrictions by offering user-friendly, non-verbal, and scalable assessments. This study investigated the diagnostic accuracy of BraincheX, a newly developed digital test battery designed with a focus on accessibility and usability, by comparing its subtest performance to equivalents of the Consortium to Establish a Registry for AD (CERAD)-Plus battery. Methods Fifty-six participants with early AD and healthy controls were recruited from the LMU hospital memory clinic. Diagnostic groups were defined by amyloid positivity and clinical expert consensus. Participants completed both the BraincheX digital battery and the CERAD-Plus assessment. A total BraincheX score was calculated by summing standardized subtest scores. Data were analyzed using receiver operating curve (ROC) analysis and the Youden Index to determine diagnostic accuracy. Correlations between BraincheX and CERAD-Plus subtests were examined, and group differences were analyzed via ANOVA. Results ROC analysis revealed strong diagnostic accuracy for the BraincheX total score in differentiating between early AD and controls (AUC = .86; optimal cut-off = -1.51), with a sensitivity of 89.7% and a specificity of 32%. BraincheX total scores correlated strongly with CERAD total scores (r = .73, p < .001). BraincheX demonstrated high internal consistency (Cronbach’s α = .84). ANOVA confirmed significant group differences across all BraincheX subtests (p < .01). Additionally, individual BraincheX subtests showed strong correlations with their CERAD-Plus equivalents, such as the Clock Drawing Test (r = .73) and TMT-B (r = .48). Discussion These findings support BraincheX as a promising, accessible digital screening tool for cognitive decline, offering advantages such as automated scoring, immediate feedback, and reduced examiner bias. Its design promotes greater equity and inclusivity in cognitive assessment. Future research is underway to validate BraincheX in larger and more diverse populations.


  • Open Access

    Development of a short version of the German subjective cognitive decline questionnaire (SCD-Q17): a principal component analysis approach to item reduction

    by Paulina Tegethoff, Robert Perneczky, Anna Hufnagel, Manolo Kehrls, Nikola Clara-Sophie Wüsten, Carolin Kurz

    Since it was shown that Alzheimer’s disease (AD) begins many years before the onset of symptoms with subjective cognitive decline (SCD), there has been increasing interest in the early clinical stages where disease-modifying drugs are expected to have the greatest benefit. However, at this early stage cognitive testing may yield unremarkable results, it is necessary to find a tool that can provide a simple and reliable indication of SCD as a part of a screening tool for AD in the general population. The German version of the 24-item Subjective Cognitive Decline Questionnaire (SCD-Q) with a dichotomous answer scale was tested, which then revealed some challenges. For this reason, an adaptation of the questionnaire was necessary. 360 participants completed the SCD-Q, all of whom were outpatients at a memory clinic. The most relevant subitems were identified by principal component analysis. This analysis focused on the self-perceived perspective of the decline. Results of the principal component analysis, consultations with experts and feedback from respondents were integrated into a short version of the SCD-Q with 17 items and a Likert scale – the SCD-Q17. The SCD-Q17 was sent to 100 participants of the original questionnaire for re-completion and, a new cut-off value was calculated by receiver operator characteristic (ROC) curves. The SCD-Q17 is a useful tool for the reliable detection of subjective symptoms, and thus may prompt more in-depth assessments of the underlying etiology. CogScreen has been retrospectively registered at clinical trials (NCT06191952).


  • Open Access

    Correction: The Open Anchoring Quest Dataset: Anchored Estimates from 96 Studies on Anchoring Effects

    by Lukas Röseler, Lucia Weber, Katharina Helgerth, Elena Stich, Miriam Günther, Paulina Tegethoff, Felix Stefan Wagner, Elitza Ambrus, Martina Antunovic, F. Barrera-Lemarchand, et al.

    This article details a correction to: Röseler, L., Weber, L., Helgerth, K., Stich, E., Günther, M., Tegethoff, P., … Schütz, A. (2022). The Open Anchoring Quest Dataset: Anchored Estimates from 96 Studies on Anchoring Effects. Journal of Open Psychology Data, 10(1), 16. DOI: https://doi.org/10.5334/jopd.67


  • Nutzung von Anschlussmaßnahmen nach stationärem Alkoholentzug

    by Daniela Reichl, Niklas Enewoldsen, Paulina Tegethoff, Taisia Gendlina, Sebastian Saur, Catharina Lang, Lukas Fuhrmann, Kiona K. Weisel, Matthias Berking, Mathias Zink, et al.

    Zusammenfassung: Zielsetzung: Die vorliegende Studie thematisiert potenzielle Schnittstellenprobleme, indem sie die Nutzung von Anschlussmaßnahmen (AN) bei Patient_innen nach stationärem Alkoholentzug ohne Nahtlosverfahren untersuchte. Methodik: Analysiert wurde die Kontrollgruppe des SmartAssistEntz-Projekts. Dazu wurden 181 Personen drei und sechs Wochen sowie drei und sechs Monate nach ihrer Entzugsbehandlung telefonisch befragt und Informationen zur Nutzung und Bewertung verschiedener AN erfasst. Ergebnisse: Über den Studienzeitraum hinweg nahm mehr als die Hälfte der Teilnehmenden mindestens eine AN in Anspruch. Am häufigsten und kontinuierlich wurden Suchtberatungsangebote genutzt (20-35 % der Teilnehmenden). Entwöhnungen wurden drei Wochen nach der Entzugsbehandlung von 8-14 %, nach sechs Monaten von 27-32 % der Teilnehmenden berichtet. Die AN wurden mehrheitlich als „hilfreich“ bewertet, wobei Selbsthilfegruppen am schlechtesten abschnitten. Das Fehlen einer AN wurde am häufigsten (12-22 %) mit Wartezeit begründet. Das Aufsuchen einer Entwöhnungsbehandlung in den ersten drei Monaten nach Entzugsbehandlung hing mit einem geringeren Rückfallrisiko zusammen. Schlussfolgerungen: Insbesondere Suchtberatungsangebote scheinen eine niedrigschwellige und als hilfreich bewertete Maßnahme im Anschluss an eine stationäre Entzugsbehandlung zu sein. Gleichzeitig scheint bezogen auf Abstinenz das Aufsuchen einer Entwöhnung ausschlaggebend zu sein, sodass deren Nutzung stärker gefördert werden sollte.